Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 PTPI | Healthcare | $0.00 | 28.08K | $119.28K | 0.00 | ― | ― |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PTPI | Petros Pharmaceuticals | 0.00 | -0.00 | -31.25% |
| Name | Price | % Change | |
|---|---|---|---|
| PTPI | $0.00 | -31.25% |
Petros Pharmaceuticals ( ($PTPI) ) just unveiled an update. On September 30, 2026, Petros Pharmaceuticals, Inc. executed a General Assignment for the Benefit of Creditors under California law, transferring all
The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). On June 18, 2026, Petros Pharmaceuticals and its Vice President of Finance, Principal Accounting Officer and Principal Financial Officer,
The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). On June 5, 2026, Petros Pharmaceuticals’ board approved grants totaling 7,000,000 restricted shares of common stock to Chairman Joshua
Petros Pharmaceuticals ( ($PTPI) ) has released a notification of late filing. Petros Pharmaceuticals, Inc. has filed a Form 12b-25 announcing a delay in submitting its Form 10-K (Yearly Report)
The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). On January 1, 2026, Petros Pharmaceuticals’ board approved, effective January 2, 2026, the grant of a total of 7,250,000
Petros Pharmaceuticals ( ($PTPI) ) has issued an announcement. Petros Pharmaceuticals, Inc. announced that its common stock will be delisted from the Nasdaq Stock Market, effective ten days after the
Petros Pharmaceuticals (PTPI) announces the strategic deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals, including its wholly owned subsidiaries, Timm Medical Technologies, Inc. and Pos-T-Vac, from its consolidated balance sheet,
Petros Pharmaceuticals ( ($PTPI) ) just unveiled an update. On March 31, 2025, Petros Pharmaceuticals‘ subsidiary, Metuchen Pharmaceuticals, terminated its license agreement with Vivus, Inc., ceasing rights to Stendra® avanafil
The latest announcement is out from Petros Pharmaceuticals ( ($PTPI) ). On May 20, 2025, Petros Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with
Petros Pharmaceuticals (PTPI) has received a staff determination letter from the Nasdaq Stock Market, informing the Company that Nasdaq determined to suspend trading and delist the Company’s common stock from
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
